Biological rationale for the therapeutic role of specific antithrombins

Coronary Artery Disease

Volumn 7, Issue 6, 1996, Pages 409-419

  Weitz, Jeffrey I ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

coronary syndromes; heparin; hirudin; thrombin

Indexed keywords

ANTITHROMBIN; ARGATROBAN; DERMATAN SULFATE; HEPARIN; HEPARINOID; HIRUDIN; HIRUGEN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN;

ACETYLATION; BLOOD CLOT LYSIS; CORONARY ARTERY DILATATION; DRUG EFFECT; DRUG MECHANISM; HEART MUSCLE ISCHEMIA; HUMAN; PRIORITY JOURNAL; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; UNSTABLE ANGINA PECTORIS;

EID: 0029777395     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-199606000-00003     Document Type: Review

References (56)

1. Fuster V, Badimon L, Badimon JJ, Chesebro JH: The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992, 326:242-250. An excellent review of the pathogenesis of acute coronary syndromes.
2. Hogg PJ, Jackson CM: Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. Proc Natl Acad Sci USA 1989, 86:3619-3623.
3. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J: Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990, 86:385-91. This study demonstrates that heparin is limited in its ability to inhibit thrombin bound to fibrin. In contrast, direct thrombin inhibitors were able to inactivate free thrombin and clot-bound thrombin equally well. These findings provide a plausible explanation for the superiority of direct thrombin inhibitors over heparin in a variety of animal model systems.
4. Bar-Shavit R, Eldor A, Vlodavasky I: Binding of thrombin to subendothelial extracellular matrix: protection and expression of functional properties. J Clin Invest 1989, 84:1096-1104.
5. Hirsh J: Heparin. N Engl J Med 1991, 324:1565-1574. An excellent review of the mechanism of action and clinical usefulness of unfractionated heparin.
6. Hirsh J, Levine MN: Low molecular weight heparins. Blood 1992, 79:1-17. An up-to-date summary of the potential advantages of low-molecular-weight heparin over standard unfractionated heparin.
7. Furie B, Furie BC: Molecular and cellular biology of blood coagulation. N Engl J Med 1992, 326:800-806.
8. Tollefsen DM: The interaction of glycosaminoglycans with heparin cofactor II. Ann N Y Acad Sci 1994, 714:21-31.
9. Rosenberg RD: The heparin-antithrombin system: a natural anticoagulant mechanism. In Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 3rd Edition. Edited by Colman RW, Hirsh J, Marder VJ, Salzman EW. Philadelphia: JB Lippincott; 1994:837-860.
10. Weitz J, Leslie B, Hudoba M: Thrombin remains bound to soluble fibrin degradation products and is partially protected from inhibition by heparin-antithrombin III [abstract]. Thromb Haemost 1991, 65:931.
11. Markwardt F: The development of hirudin as an antithrombotic drug. Thromb Res 1994, 74:1-23. A detailed review of the development of hirudin.
12. Rydel TJ, Ravichandran KG, Tulinsky A, Bode W, Huber R, Roitsch C, et al.: The structure of a complex of recombinant hirudin and human α-thrombin. Science 1990, 249:277-280.
13. Maraganore JM, Chao B, Joseph ML, Jablonski J, Ramachandron KL: Anticoagulant activity of synthetic hirudin fragments. J Biol Chem 1989, 264:8692-8698.
14. Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW II: Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990, 29:7095-7101.
15. Kline T, Hammond C, Bourdon P, Maraganore JM: Hirulog peptides with scissile bond replacements resistant to thrombin cleavage. Biochem Biophys Res Commun 1991, 177:1049-1055.
16. 2Cl. A selective affinity label for thrombin. Thromb Res 1979, 14:969-973.
17. Kettner C, Mersinger L, Knabb R: The selective inhibition of thrombin by peptides of boroarginine. J Biol Chem 1990, 265:18289-18297.
18. Bagdy D, Barabas E, Szabo G, Bajusz S, Szell E: In vivo anticoagulant and antiplatelet effect of D-PheProArgH and D-MePheProArgH. Thromb Haemost 1992, 67:357-365.
19. 2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl) sulfonyl]-L-arginyl)]-2-piperidinecarboxylic acid. Biochemistry 1984, 23:85-90.
20. Harker LA, Maraganore JM, Hirsh J: Novel antithrombotic agents. In Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 3rd Edition. Edited by Colman RW, Hirsh J, Marder VJ, Salzman EW. Philadelphia: JB Lippincott; 1994:1638-1660.
21. Gold HK, Torres FW, Garabedian HD, Werner W, Jang IK, Khan A, et al.: Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Coll Cardiol 1993, 21:1039-1047.
22. Bock LC, Griffin LC, Latham JA, Vermaas EH, Toole JJ: Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature 1992, 355:564-566.
23. Padmanabhan K, Padmanabhan KP, Ferrara JD, Sadler JE, Tulinsky A: The structure of α-thrombin inhibited by a 15-mer single stranded DNA aptamer. J Biol Chem 1993, 268:17651-17654.
24. Griffin LC, Tidmarsh GF, Bock LC, Toole JJ, Leung LL: In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits. Blood 1993, 81:3271-3276.
25. Green D, Hirsh J, Heit J, Prins M, Davidson B, Lensin AWA: Low molecular weight heparin: a critical analysis of clinical trials. Pharmacol Rev 1994, 46:89-109. A thoughtful review of the clinical trials with low-molecular-weight heparin.
26. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, et al.: Heparin-induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin N Engl J Med 1995, 332:1330-1335. A prospective study demonstrating that the frequency of heparin-induced thrombocytopenia is higher in patients randomly allocated to receive standard unfractionated heparin than it is in those given low-molecular-weight heparin. This is the best evidence yet suggesting that the risk of heparin-induced thrombocytopenia is lower with low-molecular-weight heparin therapy than it is with standard unfractionated heparin therapy.
27. Kelton JG, Smith J, Warkentin TE, Hayward CPM, Denomme GA, Horsewood P: Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 1994, 83:3232-3239.
28. Zoldhelyi P, Webster MWI, Fuster V, Grill DE, Gasper DL, Edwards SJ, et al.: Recombinant hirudin, in patients with chronic, stable coronary disease: safety, half-life and effect on coagulation parameters. Circulation 1993, 88:2015-2022.
29. Cannon CP, Maraganore JM, Loscalzo J: Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. Am J Cardiol 1993, 71:778-782.
30. Theroux P, Waters D, Lam J, Juneau M, McCans J: Reactivation of unstable angina after the discontinuation of heparin in the acute phase of unstable angina. N Engl J Med 1992, 326:141-145.
31. Fenton JW II, Olson TA, Zabinski MP, Wilner DG: Anion-binding exosite of human α-thrombin and fibrin(ogen) recognition. Biochemistry 1988, 27:7106-7112.
32. Stubby MT, Bode W: A player of many parts: the spotlight falls on thrombin's structure. Thromb Res 1993, 69:1-58. A detailed review of the structure-function relationships of thrombin.
33. Mirshahi M, Soria J, Soria C, Faivre F, Lu H, Courtney M, et al.: Evaluation of the inhibition by heparin and hirudin of coagulant activation during rt-PA-induced thrombolysis. Blood 1989, 74:1026-1030.
34. Coller BS: Platelets and thrombolytic therapy. N Engl J Med 1990, 322:33-42.
35. Lee CD, Mann KG: The activation of human coagulation factor V by plasmin. Blood 1989, 73:185-190.
36. Ewald GA, Eisenberg PR: Plasmin-mediated activation of contact system in response to pharmacological thrombolysis. Circulation 1995, 91:28-36.
37. Topol EJ, George BS, Kereiakes DJ, Stump DC, Candela RJ, Abbotsmith CW, et al.: A randomized controlled trial of intravenous plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation 1989, 79:281-286.
38. Prins MH, Hirsh J: Heparin as an adjunctive treatment after thrombolytic therapy for acute myocardial infarction. Am J Cardiol 1991, 67:3A-11A.
39. Global use of strategies to open coronary arteries (GUSTO) IIa investigators: Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994, 90:1631-1637.
40. Antmann EM for the TIMI 9A Investigators: Hirudin in acute myocardial infarction. Safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9A trial. Circulation 1994, 90:1624-1630.
41. Neuhaus KL, von Essen R, Tebbe U, Jessel A, Heinrichs H, Maurer W, et al.: Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK). Circulation 1994, 90:1638-1642.
42. Lidon RM, Theroux P, Bonan R, Lesperance J, Adelman B, Duval D, et al.: A pilot early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction. Circulation 1994, 89:1567-1572.
43. Theroux P, Perez-Villa F, Waters D, Lesperance J, Shabani F, Bonan R: A randomized double-blind comparison of two doses of hirulog or heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation 1995, 91:2132-2139.
44. Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS, et al.: A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. Am J Coll Cardiol 1994, 23:993-1003.
45. Lee LV, McCabe CH, Antman EM, Koch M, Wilensky R, Stringer K, et al.: Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the TIMI 6 trial [abstract]. J Am Coll Cardiol 1994, (special issue):344A.
46. von Essen R, Neuhaus KL, Niederer W, Tebbe U, Nebelsieck H, Roth M, for the ALKK-Group: Hirudin for improvement of thrombolysis (HIT Study): a dose escalating study [abstract]. Ann Hematol 1994, 68 (suppl II):43A.
47. Heras M, Chesebro JH, Webster MWI, Mruk JS, Grill DE, Penny WJ, et al.: Hirudin, heparin, and placebo during deep arterial injury in the pig. Circulation 1990, 82:1476-1484.
48. 2Cl in baboons. Blood 1993, 81:1762-1770.
49. Bar-Shavit R, Benezra M, Eldor A, Hy-Am E, Fenton JW II, Wilner GD, et al.: Thrombin immobilized to extracellular matrix is a potent mitogen for vascular smooth muscle cells: nonenzymatic mode of action. Cell Regulation 1990, 1:453-463.
50. Sarembock IJ, Gertz SK, Gimple LW, Owen RM, Powers ER, Roberts WC: Effectiveness of recombinant desulphatohirudin in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation 1991, 84:232-243.
51. Topol EJ, Bonan R, Jewitt D, Sigwart U, Kakkar VV, Rothman M, et al.: Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 1993, 87:1622-1629.
52. van den Bos AA, Deckers JW, Heyndrickx GR, Laarman GJ, Suryapranata H, Zijlstra F, et al.: Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty. Circulation 1993, 88:2058-2066.
53. Topol EJ, Fuster V, Harrington RA, Califf RM, Kleiman NS, Kereiakes DJ, et al.: Recombinant hirudin for unstable angina pectoris: a multicenter, randomized, angiographic trial. Circulation 1994, 89:1557-1566.
54. Sharma GVRK, Lapsley DE, Vita JA, Sharma S, Coccio E, Adelman B, et al.: Safety and efficacy of hirulog in patients with unstable angina [abstract]. Circulation 1992, 86 (suppl I):I386.
55. Lidon RM, Theroux P, Juneau M, Adelman B, Maraganore J: Initial experience with a direct antithrombin, hirulog, in unstable angina: anticoagulant, antithrombotic and clinical effects. Circulation 1993, 88:1495-1501.
56. Fuchs J, McCabe CH, Antman EM, Borzak S, Palisaitis D, Herson S, et al.: Hirulog in the treatment of unstable angina: results of the TIMI 7 trial [abstract]. Am J Coll Cardiol 1994, 23:56A.